Boehringer Ingelheim announces Phase III data of flibanserin in pre-menopausal women with HSDD

Monday, November 16, 2009 - 14:42 in Psychology & Sociology

Ridgefield, CT, November 16, 2009 - Data from pivotal Phase III clinical trials demonstrate that flibanserin 100mg increased the number of satisfying sexual events (SSE) and sexual desire (the co-primary endpoints) while decreasing the distress associated with Hypoactive Sexual Desire Disorder (HSDD).

Read the whole article on Science Blog

More from Science Blog

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net